Dr. Rosemarie Aurigemma is Chief of the Drug Development Section in the Office of Biodefense Research Resources and Translational Research at NIAID, NIH, where she directs the advancement of new therapies for existing and emerging infectious diseases important to public health such as influenza, antibiotic resistant infections, and dengue fever, as well as for infectious bioterrorism agents, such as anthrax, pandemic flu, botulism and drug resistant bacterial infections. Dr. Aurigemma collaborates with other federal agencies within the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), including the CDC, FDA, DoD, BARDA and DHS. In this role, she contributes to the establishment of policies and practices for meeting the nation’s emergency medical countermeasure needs. In 2014, Dr. Aurigemma’s group was responsible for gathering pivotal study data to advance promising drugs to treat Ebola Virus Disease. Dr. Aurigemma has also collaborated with federal colleagues on drafting the action plan to meet the objectives of the Combating Antibiotic Resistant Bacteria (CARB) initiative.
Prior to joining NIH in 2009, Dr. Aurigemma managed therapeutic product development at National Cancer Institute, NIH, where she ushered a number of novel cancer therapies to clinical trials. Her earlier experience was in a drug discovery and development and clinical development in the biotechnology industry. Dr. Aurigemma holds a PhD in Microbiology from Colorado State University and a B.S. in Biology from Cornell University.
Dr. Aurigemma will be speaking about ‘Funding programs to incentivize pre-clinical development’ at World Anti-Microbial Resistance Congress USA 2016. This session will discuss supporting the development of therapeutic alternatives to traditional antibiotics to fight antimicrobial resistance, funding for antimicrobial resistance diagnostics projects, and how these programs align with the CARB goals. To hear more from her and other industry experts, join us at World Anti-Microbial Resistance Congress USA 2016 held September 8-9 at Washington Court Hotel in Washington, DC.